See up to 3 months of GNLX. The 7-day demo opens the 1M and 3M ranges and puts GNLX on your watchlist.
Start 7-day demoLatest GNLX insider trades
Joseph Cappello - OfficerOpen-market sale$28K- Thomas Zindrick - Officer
About GENELUX Corp (GNLX)
The SEC lists GENELUX Corp under CIK 0001231457, in pharmaceutical preparations. It is grouped with Health Care companies on this site.
GNLX Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 6 | 58,732 | $159K |
GNLX insider transactions (Form 4)
3769 Form 4 filings on record, the earliest from Oct 21, 2024, newest first. Filing history page 1 of 3.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Joseph Cappello - Officer | Open-market sale | Common Stock | 10,257 | $2.74 footnote F2 | $28K | |
| ||||||
| Thomas Zindrick - Officer | Open-market sale | Common Stock | 34,463 | $2.67 footnote F2 | $92K | |
| ||||||
| Yong Yu - Officer | Open-market sale | Common Stock | 9,683 | $2.75 footnote F2 | $27K | |
| ||||||
| Yong Yu - Officer | Open-market sale | Common Stock | 653 | $2.94 footnote F2 | $2K | |
| ||||||
| Joseph Cappello - Officer | Open-market sale | Common Stock | 653 | $2.95 footnote F2 | $2K | |
| ||||||
| Thomas Zindrick - Officer | Open-market sale | Common Stock | 3,023 | $2.95 footnote F2 | $9K | |
| ||||||
 John W. Smither - Director | Open-market sale | Common Stock | 12,000 | $2.91 footnote F2 | $35K | |
| ||||||
| Matthew Pulisic - Officer | Grant or award | Common Stock | 278,906 | $0.00 | - | |
 Eric Groen - Officer | Grant or award | Common Stock | 233,957 | $0.00 | - | |
| Joseph Cappello - Officer | Grant or award | Common Stock | 174,841 | $0.00 | - | |
 James L. Tyree - Director | Grant or award | Common Stock | 28,409 | $0.00 | - | |
| James L. Tyree - Director | Grant or award | Stock Option (Right to Buy) | 31,566 | $0.00 | - | |
| Thomas Zindrick - Officer | Grant or award | Common Stock | 730,601 | $0.00 | - | |
 John Thomas - Director | Grant or award | Common Stock | 28,409 | $0.00 | - | |
| John Thomas - Director | Grant or award | Stock Option (Right to Buy) | 31,566 | $0.00 | - | |
 Mary Mirabelli - Director | Grant or award | Common Stock | 28,409 | $0.00 | - | |
| Mary Mirabelli - Director | Grant or award | Stock Option (Right to Buy) | 31,566 | $0.00 | - | |
| Yong Yu - Officer | Grant or award | Common Stock | 119,318 | $0.00 | - | |
| John W. Smither - Director | Grant or award | Common Stock | 28,409 | $0.00 | - | |
| John W. Smither - Director | Grant or award | Stock Option (Right to Buy) | 31,566 | $0.00 | - | |
 Ralph Smalling - Officer | Open-market sale | Common Stock | 192 | $2.93 | $563 | |
| John Thomas - Director | Open-market sale | Common Stock | 10,000 | $2.98 footnote F2 | $30K | |
| ||||||
| Yong Yu - Officer | Open-market sale | Common Stock | 605 | $2.97 footnote F2 | $2K | |
| ||||||
| Joseph Cappello - Officer | Open-market sale | Common Stock | 605 | $2.97 footnote F2 | $2K | |
| ||||||
| Thomas Zindrick - Officer | Open-market sale | Common Stock | 2,798 | $2.94 footnote F2 | $8K | |
| ||||||
| Ralph Smalling - Officer | Open-market sale | Common Stock | 270 | $2.98 footnote F2 | $804 | |
| ||||||
| Ralph Smalling - Officer | Open-market sale | Common Stock | 345 | $2.42 | $835 | |
| Ralph Smalling - Officer | Open-market sale | Common Stock | 240 | $2.51 | $602 | |
| Joseph Cappello - Officer | Open-market sale | Common Stock | 906 | $2.42 | $2K | |
| Yong Yu - Officer | Open-market sale | Common Stock | 906 | $2.42 | $2K | |
| Thomas Zindrick - Officer | Open-market sale | Common Stock | 3,582 | $2.42 | $9K | |
| John Thomas - Director | Open-market sale | Common Stock | 10,000 | $2.90 footnote F2 | $29K | |
| ||||||
 Jason Litten - Officer | Grant or award | Stock Option (Right to Buy) | 275,000 | $0.00 | - | |
| Yong Yu - Officer | Open-market sale | Common Stock | 3,219 | $3.36 | $11K | |
| Yong Yu - Officer | Open-market sale | Common Stock | 973 | $5.37 | $5K | |
| Thomas Zindrick - Officer | Open-market sale | Common Stock | 12,673 | $3.33 | $42K | |
| Thomas Zindrick - Officer | Open-market sale | Common Stock | 4,509 | $5.37 | $24K | |
Item 5.07
Item 1.01, 9.01
Recent GNLX Form 144 notices of proposed sale
2An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| - | - | - | - | View on EDGAR | |
| - | - | - | - |
GNLX insider trading FAQ
What is the latest insider trade for GNLX?
GENELUX Corp (GNLX) had 6 insider filings in the last 90 days, with the most recent on 2026-09-02. The full record for GNLX runs to 69 Form 4 filings, the earliest from 2024-10-21. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying GNLX stock?
No insider purchases of GNLX were filed in the last 90 days.
How many insiders are selling GNLX stock?
6 insider sales of GNLX were filed in the last 90 days, totaling $159K.
Where can I see GNLX SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects GNLX Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Joseph Cappello view on EDGAR
- - Thomas Zindrick view on EDGAR
- - Yong Yu view on EDGAR
- - Yong Yu view on EDGAR
- - Joseph Cappello view on EDGAR
- - Thomas Zindrick view on EDGAR
- - John W. Smither view on EDGAR
- - Matthew Pulisic view on EDGAR
- - Eric Groen view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where GNLX's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow GNLX with a 7-day demo
- GNLX on your watchlist
- Every GNLX Form 4 filing on record
- Up to 3 months of GNLX price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
